BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by ...
CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells. CD20 × ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Antibodies that bind to two targets are an established way of treating the blood cancer multiple myeloma. Aiming to top those medicines, AbbVie has secured rights to an early-clinical drug that works ...
CD3e molecule, epsilon (CD3E), is a single-pass type I membrane glycoprotein found on T cells. It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3 ...
Circulating tumour DNA (ctDNA) burden quantified through low-pass whole genome sequencing as an early pharmacodynamic biomarker of therapeutic response in patients enrolled on phase 1 trials. This is ...
Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results